Cell Genesys — Merger or Acquisition (August 2009)
19 slides from Cell Genesys's merger presentation, Aug 7, 2009
Slide 1: Elestrin
Elestrin = cate A008 Elestri Santex , Pharmaceuticals
Slide 2: BioSante Investment Highlights
BioSante Investment Highlights Products FDA approved product (Elestrin™) Potential “blockbuster” product (LibiGel®) Deep late stage product portfolio People Experienced management team Product development and FDA expertise Licensing and M & A expertise Finances Cell Genesys merger (announced June 30
Slide 3: BioSante Mission and Lead Product Portfolio
BioSante Mission: Develop and market products to treat unmet medical needs Lead product portfolio Calcium phosphate technology (CaP) Aesthetic medicine, e.g., facial line filler H1N1 vaccine adjuvant/drug delivery FDA submission < 12 months Male hypogonadism Bio-T-Gel™ Phase II Contraception The Pil
Slide 4: Elestrin (estradiol gel)
Indication: Once daily transdermal gel for treatment of moderate-to-severe vasomotor symptoms Symptoms: Hot flashes Market Size: Market Data [U.S. only]: Estrogen therapy (ET) market: ~$1.4 billion Transdermal segment: about $260 million Estimated to reach $400 million in 2010/11 20 million menopaus
Slide 5: LibiGel (testosterone gel for women)
Indication: Female Sexual Dysfunction (FSD) Symptoms: Lack of sexual desire, arousal or pleasure Market Size: Estimated U. S. market more than $2 billion LibiGel could be first FSD Rx product to market in U.S targeting menopausal women Status: Two SPAs Received in 2008! Two Phase III efficacy studie
Slide 6: LibiGel SPA
LibiGel® (testosterone gel for women) SPA The SPA affirms that female sexual dysfunction (FSD) is a diagnosable condition with measurable endpoints for study and therapy deserving of therapeutic options for treatment The SPA process and agreement affirms FDA agreement that the LibiGel Phase III clin
Slide 7: Comparative Results
~ 30% ~ 30% rare Application site reactions 1.56 v. 0.73* 2.13 v. 0.98* 5.0 v. 1.6* # increase active v. placebo 51%* 74%* 238%* % increase in sexual events from baseline 6 month Phase III 300 mcg/day N=533 SM 6 month Phase III 300 mcg/day N=562 SM 3 month Phase II 300 mcg/day N=46 SM Study Design B
Slide 8: Mean Change From Baseline: LibiGel vs. Intrinsa
Mean Change From Baseline p<0.05 3.4 * p<0.0001 versus baseline 5.0 * 1.6 3.9 2.6 Estrogen-treated SM women Month 1 Month 2 Month 3 Month 6 2.1 1.0 1.1 p<0.0003 LibiGel® vs. Intrinsa® Mean Change From Baseline in 4-Week Satisfying Sexual Event Rate 0 1 2 3 4 5 Placebo LibiGel 300 mcg/d Intrinsa Plac
Slide 9: LibiGel Potential Market
LibiGel® (testosterone gel for women) Potential Market Market potential for FSD is more than $2.0 billion 43% of women (18-59) experience some degree of FSD (JAMA) 31% experience low sexual desire specifically 31% of men experience sexual dysfunction 43% of women (57-85) experience low desire (NEJM)
Slide 10: Physician Need for FDA-Approved HSDD Therapy
7580 HSDD Defined Health - Pg. 11 Greater than 80% of physicians surveyed indicate that there is a need (or great need) for an FDA-approved therapy for HSDD. Executive Summary Physicians report a high level of need for an effective, safe and FDA approved product for HSDD. N= 51 Level of Need for FDA
Slide 11: HSDD Market Assumptions
7580 HSDD Defined Health - Pg. 12 Assumptions: US launch early 2011. Diagnosis rate moves from 30% to 50% with a drug labeled for HSDD and education for physicians and patients. 40% increase in current treatment rate. 30% of patients discontinue treatment due to androgenic side effects (15%) or lack
Slide 12: Limited Competition in US HSDD Market
7580 HSDD Defined Health - Pg. 13 ADIS, Companies’ websites Phase II Phase III Efficacy Flibanserin (HSDD)-Boehringer Ingelheim Luramist (HSDD)-VIVUS Testosterone Products Non-Testosterone Products Pre-Menopausal Women Menopausal Women There is limited competition in the US HSDD market as only LibiG
Slide 13: BioSante's Product Portfolio
CAP Look™ LibiGel® (testosterone gel) Female sexual dysfunction (FSD) The Pill Plus™ (birth control with androgen) Male Hypogonadism Bio-T-Gel™ (testosterone gel) Contraception Elestrin™ (estradiol gel) Early Human Clinical Late Human Clinical FDA approval / Licensees Menopausal symptoms Line-filler
Slide 14: BioSante Pharmaceuticals, Inc. Corporate Summary
BioSante Pharmaceuticals, Inc. Corporate Summary
Slide 15: Trading Data
NASDAQ BPAX Common stock outstanding 27.0 million Warrants 2.7 million ($2.50-$8.00) Employee options 2.7 million (average exercise price of $2.93) Fully diluted shares 32.4 million Trading Data
Slide 16: Financial Highlights
Cash at 6/30/09 Approximately $6.0 million Burn rate Approximately $1.2 million/month Financial Highlights
Slide 17: After Effect of Merger with Cell Genesys
After Effect of Merger with Cell Genesys Q3/Q4 NASDAQ BPAX Common stock outstanding 44.7 million Warrants 3.1 million Options 2.9 million Fully diluted shares 50.7 million Cash post-closing Approx. $25 million
Slide 18: Achieved / Expected Milestones
Achieved / Expected Milestones Close merger with Cell Genesys Late Q3/Q4 2009 Elestrin™ FDA approved and marketed Current LibiGel® Two clinical SPAs Received 2008 Three Phase III studies on-going Current Submit NDA H1 2011 Launch LibiGel Q4 2011 The Pill Plus™ Initiated Phase II clinical trials- ora
Slide 19: Elestrin
Elestrin = cate A008 Elestri Santex , Pharmaceuticals